4篇
您的检索式：作者名="Jun Terashima"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis显示文摘Bone is one of the preferred sites for the metastasis of malignant tumours,such as breast cancer,lung cancer and malignant melanoma.Tumour cells colonizing bone have the capacity to induce the expression of receptor activator of nuclear factor-κB ligand(RANKL),which promotes osteoclast differentiation and activation.Tumour-induced osteoclastic bone resorption leads to a vicious cycle between tumours and bone cells that fuels osteolytic tumour growth,causing bone pain and hypercalcaemia.Furthermore,RANKL contributes to bone metastasis by acting as a chemoattractant to bone for tumour cells that express its receptor,RANK.Thus inhibition of the RANKL–RANK pathway is a promising treatment for bone metastasis,and a human monoclonal anti-RANKL antibody,denosumab,has been used in the clinic.However,orally available drugs targeting RANKL must be developed to increase the therapeutic benefits to patients.Here we report the efficacy of the small-molecule RANKL inhibitor AS2676293 in treating bone metastasis using mouse models.Oral administration of AS2676293 markedly inhibited bone metastasis of human breast cancer cells MDA-MB-231-5a-D-Luc2 as well as tumour-induced osteolysis.AS2676293 suppressed RANKLmediated tumour migration in the transwell assay and inhibited bone metastasis of the murine cell line B16F10,which is known not to trigger osteoclast activation.Based on the results from this study,RANKL inhibition with a small-molecule compound constitutes a promising therapeutic strategy for treating bone metastasis by inhibiting both osteoclastic bone resorption and tumour migration to bone. | Yuta Nakai Kazuo Okamoto Asuka Terashima Shogo Ehata Jun Nishida Takeshi Imamura Takashi Ono Hiroshi Takayanagi | 2019 | Bone Research2019，7，1： | 8 |
| 2 | Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review显示文摘Treatment with pharmacological drugs for colorectal cancer(CRC)remains unsatisfactory.A major cause of failure in pharmacotherapy is the resistance of colon cancer cells to the drugs,creating an urgent issue.In this review,we summarize previous studies on the resistance of CRC cells to irinotecan and discuss possible reasons for refractoriness.Our review presents the following five major causes of irinotecan resistance in human CRC:(1)cellular irinotecan resistance is induced mainly through the increased expression of the drug efflux transporter,ABCG2;(2)cellular irinotecan resistance is also induced in association with a nuclear receptor,pregnane/steroid X receptor(PXR/SXR),which is enriched in the CYP3A4 gene enhancer region in CRC cells by exposing the cells to SN-38;(3)irinotecan-resistant cells possess either reduced DNA topoisomerase I(Top1)expression at both the mRNA and protein levels or Top1 missense mutations;(4)alterations in the tumor microenvironment lead to drug resistance through intercellular vesicle-mediated transmission of miRNAs;and(5)CRC stem cells are the most difficult targets to successfully treat CRC.In the clinical setting,CRC gradually develops resistance to initially effective irinotecan-based therapy.To solve this problem,several clinical trials,such as irinotecan plus cetuximab vs.cetuximab monotherapy,have been conducted.Another clinical trial on irinotecan plus guadecitabine,a DNA-methyltransferase inhibitor,has also been conducted. | Shogo Ozawa Toshitaka Miura Jun Terashima Wataru Habano | 2021 | Cancer Drug Resistance2021，4，4： | 2 |
| 3 | Tailored laparoscopic resection for suspected gastric gastrointestinal stromal tumors显示文摘 | Akira Sasaki Keisuke Koeda Toru Obuchi Jun Nakajima Satoshi Nishizuka Masanori Terashima Go Wakabayashi | 2010 | Surgery2010，，4： | 1 |
| 4 | Time-dependent Changes of Amino Acids in the Serum, Liver, Brain and Urine of Rats Administered with Theanine显示文摘 | Takehiko TERASHIMA Jun TAKIDO Hidehiko YOKOGOSHI | 1999 | Bioscience, Biotechnology, and Biochemistry1999，，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员